Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 414536, 10 pages
http://dx.doi.org/10.1155/2012/414536
Research Article

Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on Amyloid β1−40-Induced Alzheimer's Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of Amyloid β

1Department of Neurology, Show Chwan Memorial Hospital, Changhua, Taiwan
2Graduate Institute of Life Sciences, National Chung Hsing University, Taichung 40001, Taiwan
3Department of Nursing, College of Medicine & Nursing, HungKuang University (HKU), Taichung 40001, Taiwan
4School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, Taichung 40001, Taiwan
5School of Health, National Taichung University of Science and Technology, Taichung 40401, Taiwan
6Department of Veterinary Medicine, National Chung Hsing University, Taichung 40001, Taiwan
7Graduate Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40001, Taiwan

Received 13 March 2012; Accepted 23 April 2012

Academic Editor: Paul Siu-Po Ip

Copyright © 2012 Chung-Hsin Yeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder characterized by amyloid accumulation, neuronal death, and cognitive impairments. Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine and has never been used to enhance cognitive function and treat neurodegenerative disorders such as senile dementia. Whether YCTMT has a beneficial role in improving learning and memory in AD patients remains unclear. The present study showed that oral administration of YCTMT ameliorated amyloid-β- (Aβ1−40) injection-induced learning and memory impairments in rats, examined using passive avoidance and Morris water-maze tests. Immunostaining and Western Blot results showed that continuous Aβ1−40 infusion caused amyloid accumulation and decreased acetylcholine level in hippocampus. Oral administration of medium and high dose of YCTMT 7 days after the Aβ1−40 infusion decreased amyloid accumulation area and reversed acetylcholine decline in the Aβ1−40-injected hippocampus, suggesting that YCTMT might inhibit Aβ plague accumulation and rescue reduced acetylcholine expression. This study has provided evidence on the beneficial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that YCTMT may offer an alternative strategy for treating AD.